Comparable stake leader
ARMISTICE CAPITAL, LLC
SEC ownership of Calidi Biotherapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001855485.
Disclosed value leader
Polar Asset Management Partners Inc.
Comparable rows
2/47
Latest evidence
17 Aug 2026
- Public ticker
- CLDI on NYSE, CLDWW on OTC
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
ARMISTICE CAPITAL, LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
2 of 47
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
ARMISTICE CAPITAL, LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
17 Aug 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001855485
- Issuer location
- San Diego, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Calidi Biotherapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
Polar Asset Management Pa...
Comparable rows
2/47
Latest evidence
17 Aug 2026
13D/G
3/4/5
13F
Lead comparable stake: 5%
45 rows are not safely comparable across share classes.
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-8 of 47 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 5%.
2 of 47 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 2
ARMISTICE CAPITAL, LLC
5%
Gavrilov Ognian Anguelov
0.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 47 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
Reported 13D/G
· 30 Jun 2026
|
—
63,391 shares
|
$0 | 30 Jun 2026 |
| Gavrilov Ognian Anguelov |
13D/G
|
0.3%
Reported 13D/G
· 31 Mar 2026
|
$6,600
20,000 shares
|
-$224,400 | 31 Mar 2026 |
| Polar Asset Management Partners Inc. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$4,330,272
412,800 shares
|
— | 19 Oct 2022 |
| Lincoln Alternative Strategies LLC |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$430,700
730,000 shares
|
— | 20 Aug 2025 |
| First Light Acquisition Group, LLC |
3/4/5
10%+ Owner
|
—
denominator unverified
|
—
1,931,852 shares
|
— | 16 Jun 2023 |
| Stephen Thesing |
3/4/5
Chief Business Officer
|
—
denominator unverified
|
$848,779
471,544 shares
|
— | 12 Sep 2023 |
| Boris Radoslavov Minev |
3/4/5
Interim Chief Medical Officer
|
—
mixed-class rows
|
$764,024
455,818 shares
mixed-class rows
|
— | 17 Jun 2024 |
| Thomas A. Vecchiolla |
3/4/5
Director
|
—
mixed-class rows
|
$657,189
781,459 shares
mixed-class rows
|
— | 21 Dec 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$1,237.
Buys
$0
Insiders: 0
Sells
$1,237
Insiders: 1
Net
-$1,237
Shares: -850
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 850
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 850 | $0 | $1,237 | -$1,237 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 29 reporting-owner rows connected to Calidi Biotherapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
29
Largest Forms 3/4/5 holder
Polar Asset Management Partners Inc.
Net 12M change
-$1,237
Latest report
17 Aug 2026
Recent insider transactions for Calidi Biotherapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| George Peoples | CLDI | Non-Qualified Stock Options (right to buy) | Award | 4,000 | 4,000 | 17 Aug 2026 | Direct | |||
| Scott Leftwich | CLDI | Non-Qualified Stock Options (right to buy) | Award | 4,000 | 4,000 | 17 Aug 2026 | Direct | |||
| Alan R. Stewart | CLDI | Non-Qualified Stock Options (right to buy) | Award | 4,000 | 4,000 | 17 Aug 2026 | Direct | |||
| Andrew C. Jackson | CLDI | Stock Options (right to buy) | Award | 14,000 | 14,000 | 17 Aug 2026 | Direct | |||
| James A. Schoeneck | CLDI | Non-Qualified Stock Options (right to buy) | Award | 5,000 | 5,000 | 17 Aug 2026 | Direct | |||
| Eric E. Poma | CLDI | Stock Options (right to buy) | Award | 32,000 | 32,000 | 17 Aug 2026 | Direct | |||
| Antonio Fernandez Santidrian | CLDI | Stock Options (right to buy) | Award | 16,000 | 16,000 | 17 Aug 2026 | Direct | |||
| Corazon (corsee) D. Sanders | CLDI | Non-Qualified Stock Options (right to buy) | Award | 6,000 | 6,000 | 17 Aug 2026 | Direct | |||
| Allan Camaisa | CLDI | Common Stock | Sale | -1.09% | $1,237 | $1.46 | -850 | 76,952 | 12 Dec 2025 | AJC Capital, LLC |
* marks a reported price that did not pass the local price check.